DaVita Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DVA research report →
Range $215 – $287
Price Chart
About the company
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes.
- CEO
- Javier J. Rodriguez
- IPO
- 1995
- Employees
- 78,000
- HQ
- Denver, CO, US
Get TickerSpark's AI analysis on DVA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.13B
- P/E
- 12.36
- Fwd P/E
- 10.86
- PEG
- 0.40
- P/S
- 0.71
- P/B
- -17.39
- EV/EBITDA
- 8.22
- Div Yield
- 0.00%
- Gross Margin
- 30.96%
- Op Margin
- 14.84%
- Net Margin
- 6.49%
- ROE
- -133.21%
- ROIC
- 10.69%
Latest fiscal year · YoY change
- Revenue
- $13.64B+6.5%
- Gross Profit
- $3.68B-12.6%
- Op Income
- $2.01B
- Net Income
- $746.80M-20.2%
- EPS
- $10.06-8.7%
- OCF Growth
- -6.7%
- FCF Growth
- -10.6%
- 52W High
- $247.49
- 52W Low
- $101.00
- 50D MA
- $181.39
- 200D MA
- $181.75
- Beta
- 0.86
- RSI (14)
- 36
- Avg Volume
- 737.18K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
DaVita posted solid Q3 results, raised its 2026 IKC outlook, and narrowed full-year guidance while emphasizing clinical innovation and a major rollout of expanded HD dialyzers.· October 29, 2026
- Q3 adjusted operating income was $561 million and adjusted EPS was $3.82; free cash flow was $276 million.
- Full-year 2026 adjusted operating income guidance was narrowed to $2.175 billion to $2.25 billion and EPS to $14.30 to $15.20.
- IKC is outperforming expectations, with 2026 adjusted operating income now expected to be at least $65 million, up at least $25 million from prior guidance.
- The company said expanded HD dialyzer pilots across 150 centers and more than 10,000 patients were well received, with adoption above 90% among clinically eligible patients in the pilot.
- Management said U.S. dialysis was pressured by higher technology spending and some cost noise, but volume growth and mortality-driven census gains remained supportive.
Third quarter adjusted operating income was $561 million, adjusted EPS was $3.82, and free cash flow was $276 million. U.S. dialysis adjusted operating income was in line with expectations; treatment volume grew 1.2% year over year, treatments per normalized day rose about 65 basis points, and revenue per treatment increased about 1.1% year over year. Patient care cost per treatment was up 2.4% year over year, while U.S. dialysis G&A was up less than 2% excluding non-GAAP adjusted cyber expenses. International adjusted operating income was $46 million, up $20 million year over year. For 2026, DaVita narrowed adjusted operating income guidance to $2.175 billion to $2.25 billion and EPS guidance to $14.30 to $15.20, and still expects free cash flow of $1 billion to $1.25 billion. Management said IKC is now expected to contribute at least $65 million of adjusted operating income in 2026, and international full-year adjusted operating income is tracking at approximately $135 million.
Javier Rodriguez emphasized that clinical innovation is translating into both better patient outcomes and stronger business performance. He highlighted progress in fluid management, mortality improvement, and the rollout of expanded HD dialyzers, saying the company believes the technology can ultimately help support a return to 2% or greater volume growth by 2029. His tone was confident and candid, especially on policy, where he welcomed the Kidney Care National Plan’s goals but argued the economics of dialysis and the role of scale are often misunderstood.
Joel Ackerman focused on the drivers behind the quarter and the updated outlook. He said Q3 U.S. dialysis volume growth reflected improving mortality, but was partly offset by higher missed treatments, and he pointed to higher technology spend, medical supplies, and professional liability costs as the main pressure points. He also noted leverage of 3.38x consolidated EBITDA, debt expense of $150 million, and that the company has 3-year interest rate caps on about 80% of floating rate debt. On capital allocation, he said DaVita repurchased about 600,000 shares in Q3 and another 500,000 since quarter-end, including shares from Berkshire Hathaway.
Analysts focused on the new ESRD final rule, asking how the 3.5% headline increase and the TDAPA mechanics would affect 2027 reimbursement. Management said the net 2027 impact is currently estimated at 1.5% to 2%, with the TDAPA portion expected to fall materially after Q1 and through the year. Questions also centered on IKC growth and the company’s willingness to expand that business; Javier Rodriguez said DaVita now has the clinical, actuarial, and technology capabilities to pursue more business, but wants healthy contracts and aligned physician partners. Analysts also asked about the expanded HD dialyzer rollout, but management said it is too early to quantify near-term volume effects and did not expect major modality switching.
The call suggested DaVita is making tangible clinical progress, especially around fluid management and mortality, while also positioning expanded HD as a meaningful longer-term growth and outcome lever. IKC appears to be scaling profitably and management sounded more willing to grow it, which could add a new earnings stream over time.
Near-term headwinds remain from higher technology investment, ACA-related commercial mix pressure, and some cost inflation in supplies and professional liability. The new ESRD reimbursement rule is still complicated, and management said the 2027 benefit will be lower after Q1 because TDAPA payments reset quarterly, creating uncertainty beyond the first quarter.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.9%
- Shares Outstanding
- 62.90M
- Float Shares
- 61.59M
of shares held by institutions
668 13F filers
Buy/sell ratio 2.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for DVA, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Julie JohnsonHouse · TX32 | Buy | Sep 23, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Sep 23, 25 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Sep 25, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 5, 25 | Filing → |
| Jerry MoranSenate · KS | Sell | Dec 14, 23 | Filing → |
| Jerry MoranSenate · KS | Sell | Dec 14, 23 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Dec 12, 23 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Jun 12, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jun 29, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 19, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Mar 24, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Feb 14, 23 | Filing → |
| Jerry MoranSenate · KS | Sell | Dec 21, 21 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Berkshire Hathaway Inc | 28.88M | ▼ 1.22M |
| Vanguard Group Inc | 4.15M | ▼ 73.55K |
| Blackrock, Inc. | 2.73M | ▲ 272.90K |
| Vanguard Capital Management LLC | 2.26M | ▲ 157.80K |
| Morgan Stanley | 1.64M | ▲ 40.17K |
| Vanguard Portfolio Management LLC | 1.57M | ▲ 195.87K |
| Invesco Ltd. | 1.43M | ▲ 213.76K |
| State Street Corp | 1.38M | ▲ 54.82K |
| Geode Capital Management, LLC | 1.26M | ▲ 401.56K |
| Dimensional Fund Advisors LP | 1.20M | ▲ 58.08K |
| Arrowstreet Capital, Limited Partnership | 1.17M | ▲ 280.00K |
| Neuberger Berman Group LLC | 966.01K | ▲ 40.43K |
Held by 981 ETFs
Biggest fund positions in DVA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 26 | Arway Pamela M | other | 286 |
| Nov 15, 26 | DESOER BARBARA J | other | 286 |
| Nov 15, 26 | Moore Gregory J. | other | 286 |
| Nov 15, 26 | Hollar Jason M. | other | 286 |
| Nov 15, 26 | Schechter Adam H | other | 286 |
| Nov 15, 26 | Pullin Dennis W | other | 286 |
| Nov 15, 26 | Schoppert Wendy Lee | other | 286 |
| Nov 15, 26 | Rodriguez Javier | other | 5,165 |
| Nov 15, 26 | BERRY CHRISTOPHER MICHAEL | other | 1,031 |
| Nov 15, 26 | YALE PHYLLIS R | other | 286 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DVA coverage
Recent articles, reports, and earnings notes.
No research on DVA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DVA report →DaVita Expands Availability of Advanced Dialysis Therapy to Every U.S. Center
prnewswire.com · Nov 17
DaVita Expects Fewer Dialysis Treatments in Q4, but Higher Revenue per Visit Could Help Offset the Drop
marketbeat.com · Nov 13
DVA Investors Have Opportunity to Join DaVita Inc. Fraud Investigation with SBS Law
businesswire.com · Nov 12
Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses
benzinga.com · Nov 12
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA
gurufocus.com · Nov 12
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA
prnewswire.com · Nov 12
DaVita (NYSE:DVA) Shares Cross Above 200 Day Moving Average – What’s Next?
defenseworld.net · Nov 12
DaVita HealthCare (DVA) is a Top-Ranked Value Stock: Should You Buy?
zacks.com · Nov 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.